HUE032980T2 - Bombezin-analóg peptid-antagonista konjugátumok - Google Patents

Bombezin-analóg peptid-antagonista konjugátumok Download PDF

Info

Publication number
HUE032980T2
HUE032980T2 HUE09717301A HUE09717301A HUE032980T2 HU E032980 T2 HUE032980 T2 HU E032980T2 HU E09717301 A HUE09717301 A HU E09717301A HU E09717301 A HUE09717301 A HU E09717301A HU E032980 T2 HUE032980 T2 HU E032980T2
Authority
HU
Hungary
Prior art keywords
bombesin
compound
dota
gly
phe
Prior art date
Application number
HUE09717301A
Other languages
English (en)
Inventor
Helmut Maecke
Jean Claude Reubi
Rosalba Mansi
Original Assignee
Universitätsspital Basel
Universität Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39677415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE032980(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Universitätsspital Basel, Universität Bern filed Critical Universitätsspital Basel
Publication of HUE032980T2 publication Critical patent/HUE032980T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/086—Bombesin; Related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (2)

  1. SaaMlLmi ig®A¥p>iAi>k t. .Cí|iltatóftös· y pfcîS fegmtete'«mi%:^pÄ8i?l«g0fif'si8 3«!g«g#yn;
    - s képletbe ï> -\ érté H S L3 V;sgy 3. :' érkîks | ,;3, 3,4,3 vagy g, A klésAgSe lösídább egy i#Éfc§féis#ô?$< 1 kovalens kötés, Ç jeîesiïâss CM - O i: Xâii; 3->C>4ï'i '·;·1τ8^Λ1#·'¥δ1 S!íi3Cs&amp;js ä -Ills5 :··.Χ;<**$·*-Χ3η4 :';-/Η;. smhf MglsaLm XssgjskAí&amp;e D-Lkv DOra, fKTyr, Wf'tp vagy ep, ax siâljlss képfefe bàmit&amp;fikêmk m»gÄ-Ιδ-«soper*
    K jdenU-Ke §3 Ο, ! vagy ΧΟ-;, Xísa, ?eh;-Btv: -ic ÇLy vagy ß-Ab. Xua : jc!emvs.a v/kP/g4-A«3Md !|>Λ vagy 4-AmJ· XklLA, Xep idemXse Ls«, Cpa, Cbs: <>eA, C:h;v kre-huLly, kre--BuAk, Meg Nk vagy LrA-Buüiy. Ca X joknkve XL, i'r •Ol; Mflh ‘ '^,env(CHWC^Ht'%)rö%, msiy kspSsÜx-s Le ggg L:IÍÖB--C ÇL ML HyMCgk Mpies« Μ ‘T :jsí: <’<' ψ &amp; W " íz Λ <\ y.'· " £? <ν· Pi &amp; ψ y ·ίΛ W.
    Β " :Χ 5 Ρ f 1· 3 Ο ί J * I κ Ϊ 1 -I B Β ,χ· f ' B B &amp; X > X X >· # I X ^ f' Ρ X i B b·, t ψ m * β % ·ΐ· I % r :|: *** » 1 X I >1: W % t I F ί. 1. 1 t:.. f b B. B jf ? f I 3 I î 3 t 1ΙΙΓ 3 I f * f I f i t f I 3 i t i If ΐ f * f I S 3· s 3 b t T ;:· Γ P P p O s 9 Ψ S % b B 1: a P % B B r X ™ g - b r ü 3 < B i ·; 3 t á <- J X :"·: C fii X ' < X ii*
    ® -, &amp;. :Ά ~~ <8 x Si.. '< '< ./ fi ί 111 ί s s .? s g f /¾ jv' '0: M' M‘ T>. '0 "0 >->, ./? I a * * ï 8 ' J = · » > :&amp; f2 ÿ fi x -fi: I i %; % P ;&amp; B b 4 ή b i S 1 9 ;= P I i I f Ψ 1 3 i 1 k il 1. 1 3 Si: V, t JS” t'i X 3: Ä 'gf- X: -.>3 X •: ü ai: :4 4 r~ X -% % ' I. 1 9 « H t ifi i f 1 ;r * f i %: i ,.·. X S 9 SS ". 3 3 «· X 4 > t i ΐ P 3 3. < >;.. .a 3 3£. -3 P P r f I' "< ;j; .. tf; > r.r i- 0 vr i P ;L ~ ;r “fi X Îÿ ffi ÏS 4 K * -;,·! gfi S3 “· 1 îL ? i ·“ 1: V0- .*£. TB 'vf i'A: 0: 1·: .%· vj λ- E- ’Xr X ^r- $·· ::>>< 'X· X » ..., j» g- 3 1 3 f:;- r- ;;î " fii f B b '•y,. yB -p‘r <*> -ÍÍ: i i t I ·“ ·φ Ψ r.i r; k '* k < C". q y- y p 3 3 - If .¾ 3
    -I « > '«· i': %· If 3? »T % ψ -S a ™ 3- If "I Έ,. p > p ^ s. a i §r r è a s έ % ΐ; t * &amp; j* ι ρ. ρ ρ k 3. Ë % §. i £ Ρ ψ % ρ § i- Ő S - i t, ,K- Ο, ρ % 8 £ £ i Z: B é ρ * ¥ B a B il a a U jf i s * P » ^ i g P ® IL i § I ® ~ “ 1 If ο :, I j - 'i ~ f 1: ···:. a i w- i: f i i % ë P 1 -P 'f J a Q J·· f" f: f a ® 1 I" s * f 8 0 r $ i S: r $ t &amp; # î § Il a - Ü ' z: B O >r w. H ή: ii §: à 3 § â y '% ïï ή £ g Ő s 3 S f %' I P I, :::; B P I P P P # f ® O: "" O. P P ? à I i # g « ? s ! S I i II pi s * I 1: ï i « s ï î t s f jf I I Fil lia a « I s I r Ψ' k »' Il if, a »· H O < p si: S t U S: ^ I. I Ο “f # ρ Ώ ~r # |' 3 !?*
    * ρ ρ ψ 8 ί P a P:-' a :i»·: &amp; a y I ® f I 1 I X I # Í I I' I t I I r 1 I: i i: f é è f . I 1 î :# «I f .5 «a y O :i m kf p ' 3 P m, y. " y y % P «* n: - .œ f f n- y I ë t « i I f Ψ |; I i ® f, '- .8 ;<; V- f»: ;8 - ·> ·' .¾ ^ ,... 3. 3 « »i É 8 3 :S p :S; J: O: &amp; p ^ sr O -a: P XX " O ”> X'· p ~ λ p Z. P x-î· , -'· -X 3. 3 « » 3 ··; '< p; :3, III 1 I I I I I I a .<# g J g i « r s ? Ά ^ :^· '·# ^ 2 i ο ..% < I S 1, ί ti. 3 IL r 3 ti D ο· £. 1. a ο P - é £' 8 ο :r il' 3 W W :·' |3 O Z'. ;X — < ', >' y k s i m “ ;;·; f I % f s s· ; ' I fl?- i k iaêoyïKWt kü"pepud-awftgMni'd» Ionjug&amp;ium. ahoä a r*&amp;oter»pi.ihc·? hálált rtuliomikSÉd ihn a **Re, «Y. «C* «Gr. “»S* UÍT«f mi\ ^A5Js*«‘'ih, {<*í»d, "ko ''V·' ^Ré '\v ''Ίλ '*'Ήλ *' IS* íMl\n ι'"»^ ' \«i 5 ' Ηκ 'V'sím "Yb, r"S h I ' k N "·< v 'v *\ χηΛ^οΐ«* * '"ísVr-íxí, ve messvaku^&amp;va. ', Ai ! igx jspoit ST,'-ÎSL homh ·»' -'«si γ p-ptx* 3Hag<m«st.î korúján»«, ahoi s C M-Sillifez .|$pe.;ok>dé B vpacaî I! képiek; il i-rig : élïhon a : kôpkîi tss si : jefemese <.·§>· kovakn,' fcotês vagy ea> u-rmévaMt* arnâiow vggy eux? nem »ermêa&amp;îfcs vsgy egy :|keâmi.d?amte vagy--egy;.gySiïb ehamku R-, jekartése og\ Lovakns köuk. s &amp;gy VfméïOvîîV amn'kïsav vagy egy m R'onéxKeux. avimosav vagy egy Imeám .karbonsav vagy egy gvünh karbonsav, aszal a snegk<'ké*iek bogé B, és B^ egykkÿh jekakése kováién·? kökBsoi ekére és; ha Bs jekmiese egy djantin, akkor Bj jekxstéso egy karbonsav·· Η. Λ .' g\mv$nax vVínnYvMoKroKmak's.'ecpt*i ,a'U,o' s. u k^navak tn aho> a 'w n ΐνϋ·»λ>^«Β'ν a.'.»:» no^ív egy Hl. 1 S% V vogv V: áhoBoo:. képi-hl vegyük·!, ahol &amp;
    It· k#iiÉm a értékelő, k 2 vagy .5, h éneke 0, U 2 vagy 3, e 'i.>'BäV ·. -, ,k ,:s -s ev' <xN’x'eohvo < l !,' x v, s v ? W kópkibm
    ::0 értéke 1 V;; 34;k|MkB egész szón?. <! értéke k B, 1:s::4, i; vagy ík n Ψ
    ko|?Íe^Bíh 8*ptódsa NB vsgy ON.. f éttéke d, s, :>, X A > vsgv i\ g vnAs <K N -S, A A > va^y A ha 8’ j*kaité» Ok »KN«»· a 6-is^û gyűra adod «eibed a <Wa&amp;u ëyj'u0 ka™«·'1** ugndbm^. <*&amp;·.;*)> as:<m «s «ioraokoi'i vagy kdkddxvt?<V atíwcRsko» heha'dsskedy ha B püiaevs NH, ak>uí> 4 6 .#>3 NH'd 4>u>u >"xdvn a b Ki4a pj bre da* ex NA \<ο*,^0^1.15¾ v*y>'* W'»"* a? 3í?Oi'NUfn sΆ'Α -'N'<> 4ίο.{χ·Ρο Κ|,Μ'0ίΜ^\ y'S Vy'ygv yi î>iïS\'gOryy»iv>{,>fï pi ".'Oy ' ifc'd. 3.nd 4 «'yiCt&amp;Oti^dy h'P ' S ^ P ‘-S 'ï'kv \ ' >%> yïiliïÎ ! S:!ig>'i>hb cgA-i $£&amp;?:, à
    VI kàpkïbtm i c-xéke h 2y >. Ί. 2 v«g> b, ! V y t4ki' k \ \ 2 * \yi.k f\ B jdssttese O vagy }?·>, : giilsyösfäi i <>n$ke ;, 2 vagy .>, j Srj«*«' i. 2 vagy i. B jeliïiîkkÿ O. §y Az 5 » 8. ig?ííV;xmsökPmsvkiki yapp kpbsIPÉidhïg pt^d-aniu^Äi^Üog^^feSÜ»M#i·» rmegk&amp;esssl, hogy a bonsteú^ssislóg pvfd^a«$^go8*\*ä* fconjttgtttu* « ndhsdaao.v kplep (Π
    -· a Ik^lfedsen A’ Λ íK-N-éíí vaa k.: jeksdés«· aeonas A Nkadésévíg ax^d a kükhdxeggvl hogy e^egy Fadïonukhü havad; s'igssîas ko (ai kv j> sft. ÍÖ. GyógytóáM kÿvsitiaéîiy, aoxdy xmgàhgb foglalja; M "' b « sw-Mpo-rtcA jjKiwd bomk'^H-aaaïôg gvpdboiaiagoahui kooxipuixad.. bámt?H Aèt
  2. 11. -V I - H ijiCn>p'Uitok K?nrÎV'(>Ns s/enw! tetKíia·«^ ρ<·ρίχΡ)4ροχ;νυ komagàdimok Iwnsx·-\ \ \ *i>> i y-i! O "* \ i" ^ \. '* ('o '1 >!‘OV >y>0'Ü C'! ' y 'y df»*> ,' , * \y'>Uii<.<' \«RI)\k kktásra aa/vigy bbhlhggf sviyvlpjkök;, slêpyiNv# 132 llislids m21. y/ipftyphS: sapid? il(s>i#kaid'anaJög papd piggdidsis hgipgipgdk: MiPk|kÉ#h#: Nőá(Uiásáxa. amdy a kbveskc/d lépési foglalja magában: · kKhokaláycépaPnak ^11Ιβ»*Ι1 {(') âkaiânos képleki PiaPaüi-aaaiág pptid-sms^tmista kuajisgihinio? egy a(kaima.s nidäom.skSk( Ιδη?.?»«! vsgv Pnülonünül 13- Aj? l:-*t. B3P«(yíhd slöfiih ly(ksApj: hkiég;:Pi?dJiiglh îpç|d#dkâik »(Apukád 'ideyporj expiéssaáio dídkAikíiíjp ds/yápíídikdyp!| rwtammÈK k*tk»iU>t«feal «KgjeiMilKvtc aæoiguk' íhwra^i \alo sxlkââmâKi'Ssbî. ;p«ki>: » kôvHkfcÿb a \ -, wí btgbl* - !> ';!'> !\ι!Χ heaxlj&amp;k vgy betegnd; a Ixanb^'ia'SnalAg f*>]*ld><mtagontet* konjitggturo ?a4sôlbmx«lortké«t bui&amp;o* Äi^Mgkk &amp; - a ^Âl.üfcî« fàiÉî:S^I#tàss8l meg)dei»i$jA» :14. Aa I - rn sgaíymm-ok gAfssdyskí; SKabb bomlx-iúa-analóg pepud-aalaaoHiSsa konkigátiasi íaclioiannaácorxkém hat&amp;in «nemjyssâpixsk alkalma/ása bombai* 'rec^p&amp;ofcsik' «bbsÿbsM OÉ1* reespod: ixpresszáló îamofstgîok cs/vagi {ymocdk ;b gcnnmiorátk véglények képslkoîS.wsti vsld asegjaleRíiéséh?;! t'.iâs.iiïàlt képalkoib s/sr dk>â!luâ:sà;s, 15. A 14, îgêiiypo^î 5.?.efS!ît· isik.amsisàs. ahoi &amp; tiasasssiohvk s:?, alábbi cixoponbôi mcgváUb.Aots fákbi'íeg-sàplïé lâbUbsk: - pmyidsiarâk. bdeém-c auéîekeî - smkVîkk, b«Mrtve ssiéfekel:: - gavdK.mHssAkbih siroatoks îi.aiusvok * k*s*ejœs iüdâkâi<-.bH««èk;! - fcHáh^ejí kâf\ ifis'ü'aiUi'. - gasrtîoméropatteàûkus mmmtteiïmn miiotoky - fej-nyafci iapbámsejíes rákok, - ttsurohias&amp;omak és. «yd&amp;xsA laphämsojl«.« kardsoPlak, és ahol u xumoraUs és pariwmo**li> véredének az alább* csoportból megváltó« ràkbvî^ségckîv atalaah: - : psíefí1s:íiikfákí>.k. .- íííébísyísí.kabáftyísríikíxk ék . lüîsïsÿ álmirigyoékok. ?í>.As 4 **'> x«to* ,VH»t A'xoKvo *..»Uv vA k,>m >gj, .a* kî.-ρ,,χ ;83ö;hsífes>5s snsífiíxyístlgáíiiik aikalíaazása t«flK>rse|ltd va/va&amp;y tamoiabs o? p*nöimoráii* vér«<lvi»>-'kl.d tw.»s*v bbfgo ^gbnfcgedések kelésé?« vagy m«g«fás&amp;#re szolgád gyOg>*?or oksámsasara Π, A Hk îgéaypvïst «ÄllÄÄ#! a nms<.««i*k <u atibb! csapiból megválásai râkhueg? sekkre dalnak, - psxx^ssiarák, he Se értve sikkeket * emlőrák, beleérne ábéiekei x:.§as2troimes/u'nali8 smneál* íumorpk, - kissejtes tüdok&amp;rciaomák ·· mblb « ej î K ü re I no»a Ak. - gafc^óébtcropankreáiikus xcuroimlGkrm s unsorok, · faj-nyak* laphámsejtes ?ákok; - sjeutoblasatomak és -- ssy élbesö bphámsejses karp iktmák, » . al»v.: λ tumoraik e\ pm uo.-tunatss vender'ek a''bKi V ··ο$κ> 0's. >‘\'gsaL'v oU*ak\ igM^vk »» Ai\*h - prosztatarák, hekénve étieteké* es • ergon's k < j>çï Iv'kîlvç : ák Asfcsk kiv A 9 igé:Hp<>i·; xkîHîu! ka^lssíds-asAlőg isöpikkaslsigöíksig H'öSjiigájösss A egy eü^gsUhasó ;«>s<.bxó. Mgíí&amp; xgggislsnyag; vagy &amp;$«.#»&amp; &amp;1®Ä sgy lyátkslsAIgkls ?tób&amp;kíiy j|1§Ms#^ ölygn kkskféfôkïk bgdÿ Äaiasas agy mlioísíítgsáx: Ápax vagy s§y mdiôilmiakô^iikl: kapatteb # âtnélj? bágglágí fbglai «gj'-ôlÿ«» !%>Mi Äi# ^egksiämgöft ffieigisyikkgyiiä^klkssä;.
HUE09717301A 2008-03-07 2009-02-27 Bombezin-analóg peptid-antagonista konjugátumok HUE032980T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08075180A EP2100900A1 (en) 2008-03-07 2008-03-07 Bombesin analog peptide antagonist conjugates

Publications (1)

Publication Number Publication Date
HUE032980T2 true HUE032980T2 (hu) 2017-11-28

Family

ID=39677415

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09717301A HUE032980T2 (hu) 2008-03-07 2009-02-27 Bombezin-analóg peptid-antagonista konjugátumok

Country Status (32)

Country Link
US (2) US9035023B2 (hu)
EP (2) EP2100900A1 (hu)
JP (1) JP5784911B2 (hu)
KR (2) KR101734553B1 (hu)
CN (1) CN101965358B (hu)
AR (1) AR070809A1 (hu)
AU (1) AU2009221204C1 (hu)
BR (1) BRPI0909823B1 (hu)
CA (1) CA2717427C (hu)
CL (1) CL2009000537A1 (hu)
CO (1) CO6290707A2 (hu)
CR (1) CR11671A (hu)
CY (1) CY1118687T1 (hu)
DK (1) DK2252628T3 (hu)
DO (1) DOP2010000269A (hu)
EC (1) ECSP10010467A (hu)
ES (1) ES2615805T3 (hu)
HU (1) HUE032980T2 (hu)
MX (1) MX2010009843A (hu)
NZ (1) NZ587795A (hu)
PA (1) PA8818501A1 (hu)
PE (1) PE20091753A1 (hu)
PL (1) PL2252628T3 (hu)
PT (1) PT2252628T (hu)
RU (1) RU2523531C2 (hu)
SI (1) SI2252628T1 (hu)
SV (1) SV2010003660A (hu)
TW (1) TWI515011B (hu)
UA (1) UA103314C2 (hu)
UY (1) UY31693A (hu)
WO (1) WO2009109332A1 (hu)
ZA (1) ZA201006385B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380596A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptide derivatives and uses thereof
EP2380597A1 (en) 2010-04-20 2011-10-26 Technische Universität München Cyclopeptide derivatives and uses thereof
EA026443B1 (ru) * 2010-11-22 2017-04-28 Пирамаль Имэджинг Са Меченныелютецием аналоги бомбезина для лучевой терапии
WO2012156511A1 (en) * 2011-05-19 2012-11-22 Universitätsspital Basel Bombesin receptor targeting peptide incorporating a 1, 2, 3-triazole group in the backbone for preparing in vivo diagnostic and therapeutic agents
KR102190005B1 (ko) 2012-09-25 2020-12-15 어드밴스드 액셀러레이터 애플리케이션즈 유에스에이, 인코퍼레이티드. Grpr-양성 암의 검출, 진단과 치료를 위한 grpr-길항제
EP2740726A1 (en) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
EP2970154B1 (en) 2013-03-13 2021-07-07 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications
US20150217006A1 (en) * 2014-02-06 2015-08-06 Immunomedics, Inc. Al-f-18-labeled, al-f-19-labeled and ga-68-labeled gastrin-releasing peptide receptor (grpr)-antagonists for imaging of prostate cancer
US10919938B2 (en) 2014-06-06 2021-02-16 Technische Universität München Modified cyclopentapeptides and uses thereof
RU2743781C2 (ru) 2014-06-10 2021-02-25 3Б Фармасьютикалз Гмбх Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение
EP2954934A1 (en) 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
EP2954933A1 (en) 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
ES2883347T3 (es) 2014-06-16 2021-12-07 Codexis Inc Composiciones y procedimientos para atenuar y prevenir la inflamación intestinal debida a la presencia de antígenos alimentarios peptídicos en un intestino
CN104610431B (zh) * 2014-11-26 2017-12-15 南京市第一医院 一种多肽及其应用
EP3393502A4 (en) 2015-12-16 2019-06-12 Nepetx, LLC COMPOSITIONS AND METHODS OF TREATING GLUTENEAL COMPATIBILITY AND DISORDERS ARISING FROM THE DISEASE
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
WO2018126183A2 (en) * 2016-12-29 2018-07-05 The General Hospital Corporation Her3 peptides for imaging and radiotherapy
AU2018207190B2 (en) 2017-01-12 2020-12-03 Orano Med Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
RU2681318C1 (ru) * 2017-11-24 2019-03-06 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ получения иммуносупрессорного пептида Abu-TGIRIS-Abu, меченного ионом Gd3+
US20210402016A1 (en) * 2018-11-13 2021-12-30 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
EP3763726A1 (en) 2019-07-08 2021-01-13 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
WO2021005131A1 (en) 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
KR20220118464A (ko) * 2019-12-19 2022-08-25 테크니쉐 우니베르지테트 뮌헨 암의 영상화 및 치료법을 위한 개선된 약동학을 갖는 화합물
WO2021250240A1 (en) 2020-06-12 2021-12-16 Orano Diaza-18-crown-6 derivative useful for chelating radium, conjugate and radium chelate comprising the same, and uses thereof
EP3973999A1 (en) 2020-09-28 2022-03-30 Orano Med Conjugate or its salt comprising a gastrin-releasing peptide receptor antagonist and uses thereof
WO2022123462A1 (en) 2020-12-09 2022-06-16 3B Pharmaceuticals Gmbh Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
WO2023111350A2 (en) 2021-12-17 2023-06-22 3B Pharmaceuticals Gmbh Carbonic anhydrase ix ligands
WO2024052431A1 (en) 2022-09-07 2024-03-14 3B Pharmaceuticals Gmbh Prostate specific membrane antigen (psma) ligands and use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5686410A (en) * 1989-07-20 1997-11-11 Novartis Ag Polypeptide derivatives
ATE120374T1 (de) * 1989-07-20 1995-04-15 Sandoz Ag Markierte polypeptidderivate.
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5369094A (en) * 1990-11-29 1994-11-29 The Administrators Of The Tulane Educational Fund Polypeptide bombesin antagonists
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US7060247B2 (en) 1997-04-22 2006-06-13 The Curators Of The University Of Missouri Gastrin receptor-avid peptide conjugates
US6200546B1 (en) 1997-04-22 2001-03-13 The Curators Of The University Of Missouri Gastrin receptor-avid peptide conjugates
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
CA2316218A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
GR1003661B (el) * 2000-05-25 2001-09-05 Εθνικο Κεντρο Ερευνας Φυσικων Επιστημων (Εκεφε) "Δημοκριτος"... ΣΥΝΘΕΣΗ, ΒΙΟΛΟΓΙΚΗ ΚΑΙ ΠΡΟΚΛΙΝΙΚΗ ΑΞΙΟΛΟΓΗΣΗ ΑΝΑΛΟΓΩΝ ΤΗΣ (D-Phe6, Leu-NHEt13, des-Met14)-ΒΟΜΒΕΣΙΝΗΣ (6-14)ΤΡΟΠΟΠΟΙΗΜΕΝΩΝ ΜΕ ΠΑ ΡΑΓΩΓΑ ΤΟΥ 1,4,8,11-ΤΕΤΡΑΑΖΑΕΝΔΕΚΑΝΙΟΥ(1,4,8,11-TETRAAZAUNDECAN E)ΚΑΙ ΕΠΙΣΗΜΑΣΜΕΝΩΝ ΜΕ ΤΕΧΝΗΤΙΟ-99M- ΓΙΑ ΕΦΑΡΜΟΓΗ ΣΤΗΝ ΟΓΚΟΛΟΓ
AU2001223816A1 (en) * 2000-12-20 2002-07-01 Warner-Lambert Company Llc Novel uses of non-peptide bombesin receptor antagonists for treating anxiety and panic disorders
US7850947B2 (en) 2003-01-13 2010-12-14 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US7226577B2 (en) * 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7922998B2 (en) * 2003-01-13 2011-04-12 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US20080008649A1 (en) 2003-01-13 2008-01-10 Bracco Imaging S.P.A. Gastrin Releasing Peptide Compounds
CA2783275A1 (en) * 2003-07-24 2005-02-03 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for their preparation
US20090062509A1 (en) 2006-03-16 2009-03-05 Aldo Cagnolini Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
EA026443B1 (ru) * 2010-11-22 2017-04-28 Пирамаль Имэджинг Са Меченныелютецием аналоги бомбезина для лучевой терапии

Also Published As

Publication number Publication date
JP2011515338A (ja) 2011-05-19
CO6290707A2 (es) 2011-06-20
SV2010003660A (es) 2011-02-17
AU2009221204B2 (en) 2013-09-05
CR11671A (es) 2010-11-01
ECSP10010467A (es) 2010-10-30
RU2010140846A (ru) 2012-04-20
CA2717427C (en) 2016-02-23
RU2523531C2 (ru) 2014-07-20
UY31693A (es) 2010-01-05
EP2252628B1 (en) 2016-12-28
CA2717427A1 (en) 2009-09-11
TWI515011B (zh) 2016-01-01
EP2252628A1 (en) 2010-11-24
JP5784911B2 (ja) 2015-09-24
ES2615805T3 (es) 2017-06-08
KR20160128425A (ko) 2016-11-07
CN101965358B (zh) 2019-09-03
AU2009221204C1 (en) 2016-12-08
BRPI0909823B1 (pt) 2022-04-19
AR070809A1 (es) 2010-05-05
DK2252628T3 (en) 2017-02-06
PA8818501A1 (es) 2010-04-21
MX2010009843A (es) 2011-03-04
SI2252628T1 (sl) 2017-05-31
US20110097266A1 (en) 2011-04-28
KR101734553B1 (ko) 2017-05-11
BRPI0909823A2 (pt) 2019-03-06
US9035023B2 (en) 2015-05-19
EP2100900A1 (en) 2009-09-16
AU2009221204A1 (en) 2009-09-11
PT2252628T (pt) 2017-02-10
CL2009000537A1 (es) 2010-07-19
WO2009109332A1 (en) 2009-09-11
CN101965358A (zh) 2011-02-02
TW200944239A (en) 2009-11-01
US20150265733A1 (en) 2015-09-24
UA103314C2 (ru) 2013-10-10
CY1118687T1 (el) 2017-07-12
ZA201006385B (en) 2016-10-26
KR20110014565A (ko) 2011-02-11
NZ587795A (en) 2012-07-27
PE20091753A1 (es) 2009-12-13
PL2252628T3 (pl) 2017-07-31
DOP2010000269A (es) 2010-10-31

Similar Documents

Publication Publication Date Title
DK2252628T3 (en) Bombesin analog peptide antagonist conjugates
JP3647881B2 (ja) 放射性金属元素結合ペプチドの類似化合物
Valverde et al. 1, 2, 3-Triazoles as amide bond mimics: triazole scan yields protease-resistant peptidomimetics for tumor targeting.
FI101938B (fi) Polypeptidijohdannaisia
JP5308829B2 (ja) 癌の画像化および処置
Alshoukr et al. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors
US20040136906A1 (en) Gastrin releasing peptide compounds
CA2697949A1 (en) Cancer imaging and treatment
Bolzati et al. Chelating systems for 99mTc/188Re in the development of radiolabeled peptide pharmaceuticals
AU2014396468A1 (en) Modified cyclopentapeptides and uses thereof
KR20140012112A (ko) 테크네튬 표지화 펩티드
US7481993B2 (en) Chelators for radioactively labeled conjugates comprising a stabilizing sidechain
Brans et al. Synthesis and Evaluation of Bombesin Analogues Conjugated to Two Different Triazolyl‐Derived Chelators for 99mTc Labeling
CA3214915A1 (en) Radiopharmaceutical somatostatin receptor ligands and precursors thereof
CA3108450A1 (en) Cxcr4-targeted diagnostic and therapeutic agents with reduced species selectivity
CA2259950C (en) Radiometal-binding peptide analogues